Back to Journals » Cancer Management and Research » Volume 12

DW-MRI-Guided Dose Escalation Improves Local Control of Locally Advanced Nasopharyngeal Carcinoma Treated with Chemoradiotherapy

Authors Huang Y, Feng M, Yang X, Zhou J, Li L, Xu K, Xu G, Lang J

Received 18 November 2019

Accepted for publication 13 April 2020

Published 6 May 2020 Volume 2020:12 Pages 3107—3116

DOI https://doi.org/10.2147/CMAR.S239033

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Chien-Feng Li


Yecai Huang,1,2 Mei Feng,1,2 Xuegang Yang,3 Jie Zhou,2 Lu Li,2 Ke Xu,2 Guohui Xu,1,3,* Jinyi Lang1,2,*

1School of Medicine, University of Electronic Science and Technology of China , Chengdu, People’s Republic of China; 2Department of Radiation Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, People’s Republic of China; 3Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Chengdu, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Guohui Xu; Jinyi Lang
Sichuan Cancer Hospital& Institute, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, No. 55, South Renmin Road, Wuhou District, Chengdu 610000, People’s Republic of China
Tel +86-28-85420152
Email xgh0913@hotmail.com; langjy610@163.com

Background: Nasopharyngeal carcinoma (NPC) is one of the most highly radiosensitive malignancies; however, some locally advanced NPC patients experienced local recurrence even though they received aggressive treatment regimens. Defining the tumor volume precisely is important to escalate the total dose required for the primary tumor. In this study, we aimed to investigate the feasibility and efficacy of dose escalation guided by DW-MRI in patients with locally advanced NPC.
Patients and Methods: A total of 230 patients with locally advanced NPC treated with intensive modulated radiotherapy (IMRT) at Sichuan Cancer Hospital between January 2010 and January 2015 were enrolled in this retrospective study. All the patients were treated with all-course of simultaneous integrated boost-IMRT. DW-MRI-guided dose escalation with 2.2– 2.5 Gy/F, qd for 1– 3 days or 1.2– 1.5 Gy/F, bid for 1– 3 days were prescribed to 123 patients. Survival and complication of the patients were evaluated, and multivariate analysis was performed.
Results: The median follow-up of patients in the DW-MRI-guided dose-escalation group and the conventional group was 48 months (range 8– 88 months) and 52 months (range 6– 90 months), respectively. The 5-year overall survival rate, distant metastasis-free survival rate, progression-free survival, and local recurrence-free survival (LRFS) of patients in the dose-escalation group and the conventional group were 88% vs 82.5% (p = 0.244), 86.1% vs 83.3% (p = 0.741), 82.2% vs 76.6% (p = 0.286), and 89.1% vs 80.1% (p = 0.029), respectively. Multivariate analysis showed that dose escalation was independent prognostic factor for LRFS (HR 0.386, 95% CI 0.163– 0.909, p = 0.03).
Conclusion: DW-MRI-guided dose escalation is a feasible strategy to improve local control of patients with locally advanced NPC. The treatment-related complications are tolerable.

Keywords: nasopharyngeal carcinoma, DW-MRI, dose escalation, locally advanced

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]